Alkermes Plc (ALKS) has experienced challenges in growth. The company operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Over the past 4 years, Alkermes Plc has achieved a revenue compound annual growth rate (CAGR) of 10.7%.
Historical revenue and profitability trends for Alkermes Plc
The chart above illustrates Alkermes Plc's revenue trajectory over the past 4 years. The revenue pattern shows the challenges the company has faced in recent periods.
Annual percentage change in revenue and earnings
Growth rates provide insight into the momentum of Alkermes Plc's business.
How efficiently Alkermes Plc converts revenue into profit
Profit margins reveal how much of each dollar of revenue Alkermes Plc retains at different stages:
Analyst estimates and forward-looking indicators
Wall Street analysts project Alkermes Plc to continue focusing on sustainable operations. The consensus analyst rating is 4.1333 based on 15 analysts.
Based on our comprehensive analysis, Alkermes Plc (ALKS) demonstrates declining growth characteristics.
This growth analysis provides a comprehensive view of Alkermes Plc's historical performance and future outlook. Investors should consider these growth metrics alongside valuation, competitive positioning, and broader market conditions when making investment decisions. Past performance does not guarantee future results.
See how Alkermes Plc stacks up against similar companies
Explore growth analysis for top stocks
Related: ALKS Valuation, ALKS Dividend, ALKS Financial Health
Compare: ALKS vs AAPL, ALKS vs MSFT, ALKS vs GOOGL